编号：2016-003 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | ...

证券代码：300267 证券简称：尔康制药 编号：2016-002 | --- | --- | --- | |---------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------| | | | | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ □ 现场参观 | 新闻发布会 □路演活动 | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 1.国信证券 贺 ...

编号：2016-005 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------|---------------------------------------------------| | | | | | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 □其他 | □路演活动 （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 1、招商基金 2 、东兴证券 缪牧一 3 、浙商资管 戴颖 | 滕越 | | 时间 | 2016 年 9 月 14 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | 董事、副总经理 董事会秘书 | 王向峰先生 罗琅先生 | | | | | | 投资者关系活动主要内容 介绍 | 1 车间。 | 、董 ...

编号：2016-004 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 | □路演活动 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 1、海通证券 2 、海通证券 3 、光大证券 4 、光大证券 5 、广州证券 6 、国信证券 7 、银河证券 8 、兴证投资 9、上海从容投资 ...

证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 编号：2019-002 | --- | --- | --- | |-----------------------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □路演活动 | | | √ 现场参观 □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | | 财富证券谭谦、邹林原、陈骏雄、贺理、陈金鑫、徐延照等人；中泰 证券罗婷婷、张腾、李文辉、孔婷等人；湖南华州投资董建平、向 昱；信持力私募黎意平；部分个人投资者 ...

编号：2017-001 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------|------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 | □路演活动 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | | 中邮创业基金管理股份有限公司 投研部负责人 黄礴 | | 时间 | 2017 年 11 月 24 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | 董事长 董事会秘书 | 帅放文先生 罗琅先生 | | 投资者关系活动主要内容 介绍 | | | | | | 董事长帅放文先生和董秘罗琅先生与调研人员的沟通 | | | 交流主要内容如下： | ...

编号：2019-001 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------|----------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | | 深圳市君如资产管理顾问有限公司 王腾 | | 时间 | 2019 年 3 月 8 日 | | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | 董事会秘书 | 施湘燕 | | 投资者关系活动主要内容 介绍 | | | | | | 董事会秘书施湘燕女士与调研人员的沟通交流主要内 | | | 容如下： | | | | 1 | 、公司淀粉囊产品同比下降原因 ...

湖南尔康制药股份有限公司 2022 年第三季度报告 证券代码：300267 证券简称：尔康制药 公告编号：2022-034 湖南尔康制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------|-----------------|-------------------|------ ...

Group 1: Event Details - The company will participate in the "2022 Investor Online Collective Reception Day" organized by Hunan Securities Regulatory Bureau and others [1] - The event will be held online via the "Panjing Roadshow" platform on September 29, 2022, from 15:30 to 17:00 [1] - Investors can access the event through the website: http://rs.p5w.net/ [1] Group 2: Company Representatives - The company's Vice General Manager and Board Secretary, Mr. Gu Jishun, will be present for the online communication [1] - Securities Affairs Representative, Ms. Fan Yi, will also participate in the discussions with investors [1] Group 3: Investor Engagement - The event aims to enhance interaction and communication with investors, allowing them to gain a deeper understanding of the company's situation [1] - The company encourages widespread participation from investors [1]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥870,551,135.58, representing a 4.58% increase compared to ¥832,432,663.23 in the same period last year[20]. - The net profit attributable to shareholders of the listed company decreased by 67.82% to ¥30,088,115.38 from ¥103,286,458.37 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 76.34% to ¥20,453,800.23 from ¥89,417,356.64 in the same period last year[20]. - The net cash flow from operating activities was ¥68,063,584.22, down 57.42% from ¥157,267,075.66 in the previous year[20]. - Basic earnings per share decreased by 67.77% to ¥0.0146 from ¥0.0501 in the same period last year[20]. - The company's overall revenue increased by 4.58% year-on-year during the first half of 2022, despite challenges in the pharmaceutical industry[33]. - The pharmaceutical industry saw a decline in revenue of 0.6% and a profit drop of 27.6% for large enterprises in the first half of 2022[34]. - The operating costs increased by 25.97% to ¥655,273,811.78 from ¥520,169,606.85, indicating rising expenses[47]. - Research and development investment decreased by 11.49% to ¥20,410,389.00 from ¥23,060,643.70[47]. - The company reported a total of ¥135,113,770.38 in financial assets, with a fair value adjustment of ¥6,903,768.49[56]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,555,124,835.03, an increase of 2.27% from ¥5,431,979,242.78 at the end of the previous year[20]. - The total liabilities as of June 30, 2022, were CNY 578,127,762.41, up from CNY 558,277,304.57 at the start of the year, indicating a growth of about 3.00%[138]. - The company's total liabilities to total assets ratio as of June 30, 2022, was approximately 10.41%, up from 10.27% at the beginning of the year[138]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥804,615,166.47, representing 14.48% of total assets, an increase from 14.02% at the end of the previous year[52]. - Inventory increased to ¥826,999,582.27, accounting for 14.89% of total assets, up from 13.16% the previous year, indicating a 1.73% increase in proportion[52]. Business Operations - The company operates in three main business areas: excipients, active pharmaceutical ingredients (APIs), and finished drugs, with a focus on excipients as a leading domestic manufacturer[29]. - The excipients sector has shown growth, with the company developing a range of products to meet diverse customer needs[29]. - The company’s finished drug products include various injections and traditional Chinese medicine, enhancing its market presence through distribution channels[30]. - The company has adopted a "sales-driven production" model to align production with market demand[31]. - The company is responding to rising raw material prices by actively managing inventory and procurement strategies[30]. Corporate Governance and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[3]. - The company has not classified any non-recurring gains as recurring, maintaining transparency in its financial reporting[26]. - The company has received an environmental discharge permit, with the permit number 914309006828327274001P, and has conducted environmental impact assessments for all production projects[82]. - No administrative penalties were imposed on the company during the reporting period for environmental issues, indicating compliance with regulations[83]. - The company emphasizes employee rights protection, providing equal development opportunities and a comprehensive performance evaluation system[85]. Future Outlook and Strategy - The company plans to expand its production capacity for pharmaceutical intermediates and composite excipients, which may lead to management and marketing risks[70]. - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters[156]. - The company aims to improve its financial stability by optimizing its capital structure and reducing debt levels[156]. - The company is focusing on sustainability initiatives, with plans to invest in eco-friendly technologies[177]. Shareholder Information - The total number of shares is 2,062,604,870, with 31.11% (641,606,366 shares) being restricted shares and 68.89% (1,420,998,504 shares) being unrestricted shares[116]. - The largest shareholder, Shuai Fangwen, holds 41.38% of the total shares, amounting to 853,574,906 shares, with 640,181,179 shares being restricted[120]. - The company reported a total of 12,000,070 shares held in the employee stock ownership plan at the end of the reporting period, representing 0.58% of the total share capital[78]. Risk Management - The company is facing risks related to macro policy adjustments in the pharmaceutical industry, necessitating timely adjustments to management strategies[68]. - The company is exposed to foreign exchange risks due to increasing overseas projects and has established a management system for forward foreign exchange transactions[71]. - The ongoing COVID-19 pandemic has impacted the company's operations, prompting adjustments in business strategies and product structures[71].